Bryan, Garnier & Co

🌐 Bryan, Garnier & Co acts as Sole Financial Advisor to Cathay Capital and the Management of FuturMaster on an LBO led by Sagard NewGen. More about the deal: https://lnkd.in/ehB-w8cm Founded 30 years ago, FuturMaster is a leader in Supply Chain Planning and Revenue Growth Management software, empowering global companies like Heineken, L'Oréal, and TotalEnergies. With this investment, FuturMaster is set to scale innovation and expand its international reach. 🤝 This transaction adds to Bryan Garnier’s proven track record in European mid-market software space, building on transactions with EDL, Orisha, Diapason, Sinari, e-Attestations.com, Nomadia, and LACOUR GROUP. More about the deal: https://lnkd.in/ehB-w8cm #Software #SaaS #FuturMaster #SupplyChainPlanning #LBO Thibaut De Smedt, Stanislas de GMELINE, Valentin Werlé, Thomas NORMAND, Emile Neyret

🌐 Bryan, Garnier & Co acts as Sole Financial Advisor to eSmart Systems on its EUR 30m capital raise led by TiLT Capital Partners SAS, with strategic partner Quanta Services, Inc. More about the deal: https://lnkd.in/eesDXXnr   eSmart Systems is a leading provider of AI-powered solutions for the inspection and maintenance of critical infrastructure, serving over 50 utilities worldwide. This funding will help eSmart scale its AI-driven Grid Vision® solutions to further revolutionise the energy sector. 🤝 This transaction is another testament to Bryan Garnier’s expertise in supporting energy and technology-driven businesses. Previous notable energy transactions include the sale of Aidon to Gridspertise, a EUR 30m capital raise for Strohm, a USD 275m follow-on offering for Nikola Corporation, and a NOK 450m follow-on offering for Otovo. More about the deal: https://lnkd.in/eesDXXnr #AISoftware, #EnergyInfrastructure, #SmartGrid Olivier Beaudouin, Kristian Melandsø, Jay Marathe, Julien Polenne, Axel Kveim Bøe, Emeric Lampe

🌐 Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner on ONWARD Medical’s EUR 50m Follow-On Offering, anchored for EUR 22.5m by a Cornerstone Investment from Ottobock, a global leader in the fields of prosthetics and orthotics. More about the deal: https://lnkd.in/eTuqPrtM   ONWARD Medical is revolutionising therapies to restore movement, function, and independence for individuals with spinal cord injury (SCI) and movement disabilities. With 10 FDA Breakthrough Device Designations and over 270 patents issued for its innovative SCI therapies, the company is set to begin commercialisation of its first product in Q4 2024.   🤝 This transaction, the largest MedTech Follow-On Offering on Euronext in 2024, underscores Bryan Garnier’s expertise in MedTech and commitment to supporting cutting-edge healthcare innovations. Recent landmark Healthcare transactions include Egetis Therapeutics AB, Camurus, Calliditas Therapeutics, Valneva, Boiron France, Cinclus Pharma, Medincell, Abivax, and numerous others.   A special thank you to Dave Marver, Alexandre Casteau, Amori Fraser, Lorenzo Fanti, and Anne Gegenmantel for their commitment to advancing this collaboration. More about the deal: https://lnkd.in/eTuqPrtM   #Medtech #SCI #Spinalcordinjury #BCI   Pierre Kiecolt-Wahl, Paul Lequeux, Hugo Fischer

🌐 Bryan, Garnier & Co acts as Sole Financial Advisor to Cyber Guru and its shareholders on an investment round led by Riverside Acceleration Capital. More about the deal: https://lnkd.in/eA-3vvyE   Cyber Guru is a leading provider of AI/ML-based cybersecurity awareness SaaS solutions, utilising real-life scenarios and behavioural reporting metrics to train over 1 million users across 90 countries.   🌍 Cyber Guru has already established itself as a key player in the Italian cybersecurity awareness market, with strategic expansion into France and Spain. With this backing, Cyber Guru aims to accelerate AI-driven product innovation and further expand its international footprint.   This marks another landmark transaction for Bryan Garnier’s cybersecurity practice, highlighting our expertise in VC-led deals. Other notable transactions include the investment of Intera Partners in Halon, Summa Equity in NetGuardians, Seven2 in Mailinblack, Tikehau ACE Capital and Bpifrance in Vade, and the investment of Parquest in Advens.   More about the deal: https://lnkd.in/eA-3vvyE   Gianni Baroni    Olivier Beaudouin, Sanjin Goglia, Martin Eichler, Viktoryia Marchanka, Cyrine MANAI, Nicolas Plovier    Educapital P101 Adara Ventures    #Cybersecurity #Software #CyberGuru #IndustrialTech 

🔍 What were the biggest drivers of market activity in Q3 2024? And what’s on the horizon? 🔗 https://lnkd.in/g_e9QVfs 📊 Bryan Garnier is excited to share our latest market insights, highlighting key developments across Private Placements, ECM, and Debt Capital Solutions, along with deep dives into Healthcare, Software & Fintech, Energy Transition & Sustainability, Industrial Tech, Business & Tech-Enabled Services, and NextGen Consumer sectors. 🎥 Hear from our Chairman, Clifford Siegel, as he gives an overview of Q3 and outlooks that are shaping the future, as well as Bryan Garnier’s pivotal role in navigating and facilitating major transactions in challenging markets. Greg Revenu, Hervé Ronin, Olivier Beaudouin, Falk Mueller-Veerse, Thibaut De Smedt, Stanislas de GMELINE, Guillaume Nathan, Tor Berthelius, Jonathan BOHBOT, Paul de Mestier, Florent Roulet, Andreas Kulcsar, Pierre Kiecolt-Wahl, Christophe Alleman #BryanGarnier #QuarterlyReport

📢 Bryan Garnier is pleased to announce the appointment of Vincenzo Di Nicola as Partner within our Healthcare team: https://lnkd.in/e66MSkPz With over 20 years of experience in investment banking focused on transatlantic healthcare transactions, Vincenzo’s expertise will further strengthen our advisory capabilities across Europe and the US, supporting our commitment to Life Sciences and Healthcare innovation. 🎯 As we continue expanding our pan-European healthcare presence, Vincenzo’s arrival reinforces our position as a leading advisor to top-tier international healthcare companies. 🔗 Read more here: https://lnkd.in/e66MSkPz #Healthcare #InvestmentBanking #TeamExpansion #BryanGarnier 

💼 Did you know IBD can significantly impact a person’s ability to work, with nearly 50% of patients reporting a reduced capacity for daily tasks? This highlights the need for treatments that improve both symptoms and quality of life. https://lnkd.in/emmdNdx5 🔬 In this epsiode of BG Growth Series, we feature Abivax, a pioneering biotechnology company transforming the way we approach IBD treatment by harnessing the body’s natural immune-regulatory mechanisms. 🎥 We sat down with Marc de Garidel, CEO of Abivax, and Corinna zur Bonsen, Board Member, to discuss their relentless pursuit of innovation and their vision for the future of medicine. 💊 Abivax’s lead drug candidate, obefazimod, currently in Phase 3 clinical trials for ulcerative colitis, could revolutionise the management of chronic conditions. Abivax partnered with Bryan, Garnier & Co for a record-breaking USD 236 million Nasdaq IPO, the largest ever by a French biotech. 👉 Watch this BG Growth Series episode to learn more about Abivax’s journey and their mission to transform global healthcare: https://lnkd.in/emmdNdx5 Pierre Kiecolt-Wahl, Vincent Meunier, Theodore de Charsonville, Hugo Fischer Didier Blondel, Patrick Malloy, Sophie LACOURREGE #IBD #Biotech #Innovation #Healthcare #BGGrowthSeries #GrowthJourney

👓 "It is fascinating to witness how operators continue to sell a seemingly simple product, namely corrective vision, in so many different ways and generate attractive margins," observes Andreas Kulcsar, Managing Director at Bryan Garnier. https://lnkd.in/eifqfBw9 Bryan, Garnier & Co and bloobloom were pleased to host "2025 Vision: What Lies Ahead for the Optics Industry" yesterday evening at bloobloom’s Covent Garden store.   This insightful event offered a deep dive into:  ● The evolving developments in the optics industry  ● The strategic priorities of market leaders and disruptors  ● Insights from recent M&A deals and their future impact     🥂 The event was a lively networking session over drinks and canapés, where attendees connected and exchanged insights in a relaxed atmosphere.     📑 Want to learn more about this dynamic industry? Download the event presentation here: https://lnkd.in/eifqfBw9      #Optics #OpticsIndustry #FutureOfOptics #BryanGarnier #Bloobloom

🚀 Are you ready to navigate the complexities of company-led secondaries? https://lnkd.in/d4KEwrHV   In a recent webinar, Co-Head of Secondaries David Laroque 🌔 and Pierre H Leroy 🌒 explored the growing momentum of company-led secondaries, emphasising the need for expert advisory and technology to ensure smooth execution.   For further insights, our white paper "Demystifying Company-Led Secondaries" authored by Secondaries Analyst Ramsey Daunch provides a comprehensive overview of these transactions for venture-backed companies, highlighting: 📈 The evolving venture secondary market  🎯 Top strategies for a seamless liquidity process  🔑 Proactive measures for managers to meet shareholders' liquidity needs    🔗 Learn more about company-led secondaries and download the white paper here: https://lnkd.in/d4KEwrHV   #CompanyLedSecondaries #PrivateEquity #VC #BryanGarnier #WhitePaper

🎯 Bryan Garnier’s Business & Tech-Enabled Services team is a part of shaping the future, driving innovation and delivering excellence across key sectors while supporting major industry transformations. 🚀 By leading the way with strategic advisory across engineering, digital agencies, and consulting, the team is empowering clients to achieve long-term success. 🔎 Explore our key highlight deals from H1 and see how we are driving growth for our clients. https://lnkd.in/en6eQeRj Guillaume Nathan, Tor Berthelius, Pierre-Georges Roy, Sebastian Schirl, Marc Picard, Nicolas de Quincerot, Eric MADAR #TeamSuccess #Innovation #BryanGarnier